NCT00281242|Completed
Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Innate and Adaptive Immunity in COPD Exacerbations: Severe AE-COPD Clinical Course Study
Loading search results
Innate and Adaptive Immunity in COPD Exacerbations: Severe AE-COPD Clinical Course Study
Sponsor study identifier
Secondary identifiers
NIH
observational
37
1 country
1
Study Start
September 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2010
Actual (reported)Study Completion
July 2010
Actual (reported)The purpose of this study is to determine whether there is a statistical association between changes in sputum serial levels of two cytokines, interleukin (IL)-17 and IL-6, during the treatment course of a severe acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) and during the clinical course itself (i.e., rate of recovery or potential complicated course). AE-COPD is defined as an episode requiring emergency room (ER) evaluation.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2010
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2005
Date type not reportedThis date has not been verified as actual or estimated.
January 20, 2006
Actual (reported)January 24, 2006
Actual (reported)June 2010
Actual (reported)July 2010
Actual (reported)biomarker analysis at the time of exacerbation, no clinical outcome
at each exacerbation
All participants undergo the same testing in this observational trial. There is no randomization, and no interventions other than blood drawing.
All subjects undergo blood draws at study visits and at the time of COPD exacerbation visits.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Emergency room and clinics
University of Michigan at Ann Arbor
Ann Arbor, Michigan, 48105, United States
Curtis JL, Freeman CM, Hogg JC. The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research. Proc Am Thorac Soc. 2007 Oct 1;4(7):512-21. doi: 10.1513/pats.200701-002FM.
Freeman CM, Curtis JL, Chensue SW. CC chemokine receptor 5 and CXC chemokine receptor 6 expression by lung CD8+ cells correlates with chronic obstructive pulmonary disease severity. Am J Pathol. 2007 Sep;171(3):767-76. doi: 10.2353/ajpath.2007.061177. Epub 2007 Jul 19.
Jeffrey L. Curtis
University of Michigan at Ann Arbor
37 participants (actual enrollment reported by the registry).
First Submitted
January 20, 2006
First Posted
January 24, 2006
Study Start
September 2005
Date type not reportedThis date has not been verified as actual or estimated.
Comparison of Two Programs to Encourage Physical Activity in Individuals With Chronic Obstructive Pulmonary Disease
Contact the study team to confirm eligibility.
Freeman CM, Han MK, Martinez FJ, Murray S, Liu LX, Chensue SW, Polak TJ, Sonstein J, Todt JC, Ames TM, Arenberg DA, Meldrum CA, Getty C, McCloskey L, Curtis JL. Cytotoxic potential of lung CD8(+) T cells increases with chronic obstructive pulmonary disease severity and with in vitro stimulation by IL-18 or IL-15. J Immunol. 2010 Jun 1;184(11):6504-13. doi: 10.4049/jimmunol.1000006. Epub 2010 Apr 28.
Freeman CM, Martinez FJ, Han MK, Ames TM, Chensue SW, Todt JC, Arenberg DA, Meldrum CA, Getty C, McCloskey L, Curtis JL. Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009 Dec 15;180(12):1179-88. doi: 10.1164/rccm.200904-0552OC. Epub 2009 Sep 3.
Freeman CM, Martinez CH, Todt JC, Martinez FJ, Han MK, Thompson DL, McCloskey L, Curtis JL. Acute exacerbations of chronic obstructive pulmonary disease are associated with decreased CD4+ & CD8+ T cells and increased growth & differentiation factor-15 (GDF-15) in peripheral blood. Respir Res. 2015 Aug 5;16(1):94. doi: 10.1186/s12931-015-0251-1.
Primary Completion
June 2010
Actual (reported)Study Completion
July 2010
Actual (reported)Last Updated
January 29, 2016
Record last verified: 2016-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: